Analysis: Biotech Financing Slowdown Hits Early-Stage Pharmaceutical Research
Wall Street Journal
Investment in biotechnology has been stalling, and while analysts say there is no danger to industry-wide contagion, smaller companies focusing on early-stage drug development may be at risk.